Oblique Therapeutics has developed high affinity, stimuli-selective antibodies against the pain receptor TRPV1 in order to maximize pain relief and circumvent side effects.
Oblique Therapeutics has developed a pipeline of mutant selective aKRAS mAbs where the most advanced program targeting the KRAS G13D mutation has shown efficacy in a colorectal cancer xenograft model.
